Cancer patients get continued access to promising drug in rollover study

NCT ID NCT02955940

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study offers continued treatment with ruxolitinib (alone or with other cancer therapy) to people with pancreatic, colorectal, breast, or lung cancer who were already benefiting from it in a previous Incyte-sponsored trial. Participants must have stable disease and be tolerating the treatment well. The main goal is to monitor side effects and keep providing the drug until it stops working or the patient can no longer take it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Instytut Hematologii I Transfuzjologii

    Warsaw, 02-776, Poland

  • New York Oncology Hematology Pc.

    Clifton Park, New York, 12065, United States

  • Renovatio Clinical Consultants Llc

    The Woodlands, Texas, 77380, United States

  • Samodzielny Publiczny Szpital Kliniczny

    Lublin, 20-081, Poland

  • Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii

    Krakow, 31-501, Poland

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • UCLA Healthcare Hematology-Oncology

    Santa Monica, California, 90404, United States

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.